Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis
This study has been terminated.
First Posted: July 25, 2007
Last Update Posted: August 24, 2010
Information provided by:
The primary objective of the study is to explore the efficacy and safety of ATryn® (antithrombin alfa) for the treatment of disseminated intravascular coagulation (DIC) associated with severe sepsis, when administered by continuous intravenous (IV) infusion over five days.
|Disseminated Intravascular Coagulation||Drug: antithrombin alfa (INN name)||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Exploratory Efficacy and Safety, Pharmacokinetics and Dose Finding Study of ATryn® (Antithrombin Alfa) in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by LEO Pharma:
Primary Outcome Measures:
- Patients alive on day 28 having had an improvement in DIC score and having had no worsening on organ failure score.
Secondary Outcome Measures:
- Mortality at 28 and 90 days. Change in organ failure score and DIC score. Pharmacokinetic (PK) parameters.
|Study Start Date:||July 2007|
|Study Completion Date:||March 2009|
Contacts and Locations
No Contacts or Locations Provided